Orphazyme plans to lay off most of its staff following a string of failures for lead ‘pipeline-in-a-product’

Rémi Droller

Danish biopharma Orphazyme has been on a roller coaster of a ride lately, and the company plummeted down a bit further on Monday with the announcement that it will lay off two-thirds of its workforce.

The news comes nearly two months after arimoclomol,...

Click to view original post